YK-2-69 is a highly selective DYRK2 inhibitor which specifically interacts with Lys-231 and Lys-234 in the co-crystal structure. Especially, YK-2-69 exhibits more potent anti-PCa efficacy than the first-line drug enzalutamide in vivo.
Uses
YK-2-69 is a highly selective DYRK2 inhibitor with an IC50 value of 9nM. YK-2-69 specifically interacts with Lys-231 and Lys-234 of DYRK2 and can be utilized in researches related to prostate cancer[1].
IC 50
DYRK2: 9 nM (IC50)
References
[1] Yuan K, et al. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nat Commun. 2022 May 25;13(1):2903. DOI:10.1038/s41467-022-30581-4
